****Published April 2015****

MarketVIEW: Ebola virus vaccines (CAT: VAMV061)

Product Name	:	**MarketVIEW:** Ebola virus vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (.pdf) + 1 forecast model (.xls)
Therapeutic Area	:	Novel vaccines
Publication date	:	April 2015
Catalogue No	:	VAMV061

Background

The **Ebola virus** is a member of the *Filoviridae* family, which can cause a zoonotic disease in humans. The virus can be transmitted between humans *via* contact with infected body fluids or large droplets of infected fluids, causing a sudden disease with flu-like symptoms, digestive disorders and hemorrhaging. The mean case fatality of historical outbreaks[1] is around 65%. Most Ebola outbreaks occur in central Africa, although latest outbreak is focused on West Africa with around 25,000 cases and over 10,000 deaths (March 2015). It is estimated that the West African region will lose between $3.6 and $4.9 billion in GDP per year for the next 3 years (UNDP figures).

A number of manufacturers are investigating Ebola vaccines in clinical studies. Major companies involved include Okairos/NIAID (GSK), Newlink/PHAC/Merck & Co, Johnson & Johnson. The most advanced in cAd3-EBOZ in Phase II/III Okairos/NIAID (GSK). A number of small molecules, gene silencing technologies and monoclonal antibodies are also being investigated.

This **MarketVIEW** product contains a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Ebola vaccines across relevant African countries until 2030. The model contains value ($ m) and volume (mio doses) predictions per vaccine type[2]/per LO/BASE/HIGH scenarios along with timeframe, pricing and penetration estimates for all target populations/stockpile maintenance. The product also includes an in depth review of latest Ebola epidemiological trends, treatments/guidelines and latest developments in R&D.

[1] Excluding 2014/2015 outbreak
[2] Single-dose, monovalent, first-generation vaccine, Prime-boosted, polyvalent vaccine & Single-dose, polyvalent, second-generation vaccine

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44 (0) 1279 654514 e-mail: info@vacZine-analytics.com

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Ebola virus, current and past outbreaks. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel vaccines has also been utilised.

PRODUCT CONTENTS:

Published April 2015 (CAT No: VAMV061)

****This product is composed of one forecast model (.xls) and a summary presentation (.pdf)

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** info@vacZine-analytics.com

Continued.....

PAGES: ~82 MS slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model TX vaccine (MS Excel-based)

Continued.....

Summary volume and value.
Low scenario.
Base scenario.
Hi scenario
High risk infants =>
Guinea
Liberia's 26th of May 20
Sierra Leone
DRC
Congo
Gabon
South Sudan
Uganda
Medium risk infants =>
Benin + Burkina Faso
Cameroon + Ghana
Guinea-Bis + Mali
Mauritania + Nigeria
Senegal + Gambia
Togo + Burundi
CAR + Cote D'Ivoire
Kenya + Sudan
Ethiopia + Rwanda
Tanzania + Zambia
Angol + Eq Guinea
Adult Catch-ups =>
Guinea + Liberia
Sierra Leone + Gabon
DRC + Congo
South Sudan + Uganda
Senegal + Guinea-Bissau
Mali + Cote D'Ivoire
Cameroon + CAR
Eq Guinea + The Gambia
Mauritania + Burkina Faso
Ghana + Kenya
Zambia + Angola
Togo + Benin
Nigeria + Sudan
Ethiopia + Rwanda
Burundi + Tanzania
Source data
Birth cohorts
High birth cohort
Infant mortality
Adults 15 yrs
YFV coverage (WHO)
Back page

Worksheets ~ 55 interconnected

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** info@vacZine-analytics.com

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **$8995.00**/ GBP **£5800.00#** (Region license)*
- PRESENTATION OR MODEL ONLY - USD **$4995** (Region license)*

Indicative rate only. Prevailing rate applied to date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.

BIBLIOGRAPHY

1. Chippaux JP. Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga. J. Venom. Anim. Toxins Incl. Trop. Dis. 2014;20:44.
2. Na W, et al. Ebola outbreak in Western Africa 2014: what is going on with Ebola virus? Clin. Exp. Vaccine Res. 2015;4:17.
3. Osterholm MT, et al. Transmission of Ebola viruses: what we know and what we do not know. mBio. 2015;6:e00137-15.
4. Judson S, et al. Understanding Ebola virus transmission. Viruses 2015;7:511.
5. Kanapathipillai R. Ebola virus disease – current knowledge. N. Engl. J. Med. 2014;371:e18.
6. Goeijenbier M, et al. Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis. Neth. J. Med. 2014;72:442.
7. T4taylor (talk). Original uploader was T4taylor at en.wikipedia. http://commons.wikimedia.org/wiki/File:Ebola.svg Accessed March 2015.
8. West TE & Saint Andre-von Arnim A. Clinical Presentation and Management of Severe Ebola Virus Disease. Ann. Am. Thorac. Soc. 2014;11:1341.
9. UN. Global Ebola Response. Data on the Ebola outbreak. 2015. http://ebolaresponse.un.org/data Accessed March 2015.
10. MacNeil A & Rollin PE. Ebola and Marburg Hemorrhagic Fevers: Neglected Tropical Diseases? PLoS. Negl. Trop. Dis. 2012;6(6):e1546.
11. CDC. Ebola virus disease distribution map. 2015. http://www.cdc.gov/vhf/ebola/outbreaks/history/distribution-map.html#modalIdString_CDCImage_0 Accessed March 2015.
12. CDC. Ebola in Guinea. 2015. http://wwwnc.cdc.gov/travel/notices/warning/ebola-guinea Accessed March 2015.
13. NHS Choices. Ebola virus disease: an overview. 2015. http://www.nhs.uk/conditions/ebola-virus/pages/ebola-virus.aspx#UK Accessed March 2015.
14. WHO. One year into the Ebola epidemic: a deadly, tenacious and unforgiving virus. 2015. http://www.who.int/csr/disease/ebola/one-year-report/introduction/en/ Accessed March 2015.
15. CDC. 2014 Ebola Outbreak in West Africa - Reported Cases Graphs. 2015. http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/cumulative-cases-graphs.html Accessed March 2015.
16. West Africa Ebola 2014 13 Reported Cases per Week by Malanoqa - Own work. Licensed under CC BY-SA 4.0 via Wikimedia Commons - http://commons.wikimedia.org/wiki/File:West_Africa_Ebola_2014_13_Reported_Cases_per_Week.png#mediaviewer/File:West_Africa_Ebola_2014_13_Reported_Cases_per_Week.png Accessed March 2015.
17. WHO. Ebola situation report – 25 March 2015. http://apps.who.int/ebola/current-situation/ebola-situation-report-25-march-2015 Accessed March 2015.
18. BBC. Ebola: mapping the outbreak. 2015. http://www.bbc.co.uk/news/world-africa-28755033 Accessed February 2015.
19. UNDP. Socio-economic impact of Ebola in West Africa. 2015. http://www.africa.undp.org/content/rba/en/home/library/reports/socio-economic-impact-of-the-ebola-virus-disease-in-west-africa/ Accessed March 2015.
20. Berkley S. Second high-level meeting on Ebola vaccine access and financing. 2015. http://who.int/mediacentre/events/2015/S5.1_Berkley_GAVI_ebola_vaccine_investment.pdf Accessed March 2015.
21. WHO. Infection prevention and control guidance summary. 2014. http://www.who.int/csr/resources/publications/ebola/evd-guidance-summary/en/ Accessed March 2015.
22. WHO. Clinical management of patients with viral haemorrhagic fever. 2014. http://apps.who.int/iris/bitstream/10665/130883/2/WHO_HSE_PED_AIP_14.05.pdf?ua=1 Accessed March 2015.
23. CDC. What is contact tracing? 2014. http://www.cdc.gov/vhf/ebola/outbreaks/what-is-contact-tracing.html Accessed March 2015.
24. Sissoko D, et al. Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea. CROI 2015;abstract 103-ALB.
25. Triangle Business Journal. Why Chimerix stopped its Ebola program in Liberia. 2015. http://www.bizjournals.com/triangle/news/2015/02/06/why-chimerix-stopped-its-ebolaprogram-in-liberia.html Accessed March 2015.
26. Clinicaltrials.gov. A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430. 2014. https://www.clinicaltrials.gov/ct2/show/NCT02319772 Accessed March 2015.
27. Geisbert TW, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375:1896.
28. Bloomberg Business. Ebola Drug by Tekmira May Be Used on Infected Patients. 2014. http://www.bloomberg.com/news/articles/2014-08-07/ebola-drug-by-tekmira-may-be-used-on-infected-patients-fda-says Accessed March 2015.

29. Tekmira. Tekmira Establishes Manufacturing and Clinical Trial Agreement to Provide TKM-Ebola-Guinea for Clinical Studies in West Africa. 2014. http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=888660 Accessed March 2015.
30. Sarepta Therapeutics. News release. 2014. http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=1978732 Accessed March 2015.
31. Choi WY, et al. Progress of vaccine and drug development for Ebola preparedness. Clin. Exp. Vaccine Res. 2015;4:11.
32. Qiu X, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47.
33. Clinicaltrials.gov. Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection. 2015. https://clinicaltrials.gov/ct2/show/NCT02363322 Accessed March 2015.
34. Geisbert TW. Emergency Treatment for Exposure to Ebola Virus: The Need to Fast-Track Promising Vaccines. JAMA 2015 Mar 5. doi: 10.1001/jama.2015.2057. [Epub ahead of print].
35. Mullan Z. Ebola vaccines: an uncertain future? Lancet Glob. Health. 2015 Mar;3(3):e113. doi: 10.1016/S2214-109X(15)70083-5.
36. Wellcome Trust/CIDRAP. Recommendations for accelerating the development of Ebola vaccines. 2015. http://www.cidrap.umn.edu/sites/default/files/public/downloads/ebola_virus_team_b_report-final-021615.pdf Accessed March 2015.
37. Rampling T, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report. N. Engl. J. Med. 2015 Jan 28 [Epub ahead of print].
38. Kanapathipillai R, et al. Ebola Vaccine — An Urgent International Priority. N. Engl. J. Med. 2014;371:2249.
39. Stanley DA, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 2014;20:1126.
40. Clinicaltrials.gov. A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland. 2015. https://clinicaltrials.gov/ct2/show/NCT02289027 Accessed March 2015.
41. Clinicaltrials.gov. Partnership for Research on Ebola Vaccines in Liberia (PREVAIL). 2015. https://clinicaltrials.gov/ct2/show/NCT02344407 Accessed March 2015.
42. Marzi A, et al. Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections. J. Bioterror Biodef. 2011;Suppl 1 (4):doi:10.4172/2157-2526.S1-004.
43. Lai L, et al. Emergency Postexposure Vaccination With Vesicular Stomatitis Virus–Vectored Ebola Vaccine After Needlestick. JAMA. 2015;doi:10.1001/jama.2015.1995.
44. WHO. Ebola vaccines, therapies, and diagnostics. 2015. http://www.who.int/medicines/emp_ebola_q_as/en/# Accessed March 2015.
45. WHO. Ebola vaccine efficacy trial ready to launch in Guinea. 2015. http://www.who.int/mediacentre/news/releases/2015/ebola-vaccine-trial/en/# Accessed March 2015.
46. Getz WM, et al. Tactics and Strategies for Managing Ebola Outbreaks and the Salience of Immunization. Comp. Math. Methods Med. 2015;doi:10.1155/2015/736507.
47. WHO Africa. WHO and Partners agree on a common approach to strengthen Ebola preparedness in unaffected countries. 2014. http://www.afro.who.int/en/media-centre/pressreleases/item/7079-who-and-partners-agree-on-a-common-approach-to-strengthen-ebola-preparedness-in-unaffected-countries.html Accessed March 2015.
48. GAVI Alliance. Supply and procurement roadmap: yellow fever. 2013. www.gavi.org/library/gavi.../yellow-fever-roadmap-public-summary/ Accessed March 2015
49. Kinfu Y, et al. The health worker shortage in Africa: are enough physicians and nurses being trained? Bull. World Health Organ. 2009;87:225
50. US Department of Defense. DoD releases breakdown of Ebola response effort. 2015. http://www.defense.gov/news/newsarticle.aspx?id=123935 Accessed March 2015.
51. WHO. WHO-UNICEF estimates of YFV coverage. 2014 http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoverageyfv.html Accessed March 2015.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as "The Company"). (Herein [enter client name] to as "The Client").

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.

2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.

3. Cancellation policy. The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.

4. Cancellation rights: For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.

5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.

6. If not purchased on line invoices are payable within **thirty days** of the invoice date.

7. All proposals are quoted in **$USD dollars or £GBP** and invoices are to be settled in the same currency.

8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com